Burning Rock Biotech (BNR) Operating Leases (2021 - 2026)

Burning Rock Biotech's Operating Leases history runs 6 years deep, the most recent figure standing at $4.0 million for Q1 2026.

• In Q1 2026, Operating Leases rose 47.88% year-over-year to $4.0 million; the TTM figure through Mar 2026 stood at $4.0 million (up 47.88% YoY), while the FY2025 annual figure was $5.9 million, down 17.77% from the prior year.
• Operating Leases for Q1 2026 stood at $4.0 million, up from $3.4 million in the prior quarter.
• The five-year high for Operating Leases was $11.1 million in Q2 2024, with the low at $512494.5 in Q4 2023.
• The 5-year median for Operating Leases is $2.7 million (2025), against an average of $3.6 million.
• The sharpest annual moves came in 2023 and 2024: Operating Leases slumped 82.32% in 2023, then soared 1387.14% in 2024.
• Burning Rock Biotech's Operating Leases stood at $1.9 million in 2022, then tumbled by 73.1% to $512494.5 in 2023, then surged by 653.92% to $3.9 million in 2024, then decreased by 10.75% to $3.4 million in 2025, then rose by 17.07% to $4.0 million in 2026.
• Business Quant data shows BNR's Operating Leases at $4.0 million in Q1 2026, $3.4 million in Q4 2025, and $2.0 million in Q3 2025.